Matches in SemOpenAlex for { <https://semopenalex.org/work/W4251268891> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- W4251268891 endingPage "A584" @default.
- W4251268891 startingPage "A583" @default.
- W4251268891 abstract "Results from real-world studies suggest reduced hospital length-of-stay, intravenous (IV) length-of-therapy (LOT), and costs in patients with invasive aspergillosis (IA) treated with voriconazole compared to liposomal amphotericin B (LAMB) or caspofungin therapy. We performed a cost analysis comparing voriconazole, LAMB, and caspofungin as first-line treatment for IA among patients with prolonged neutropenia or undergoing bone marrow or hematopoietic stem-cell transplantation (BMT/HSCT) from a payer perspective in Lebanon. A decision analytic model with a 6-week time horizon was constructed to estimate voriconazole, LAMB, and caspofungin treatment costs (2016 US$) in Lebanon. Each treatment pathway was defined by probabilities of event occurrence and clinical outcome costs derived from published literature or local expert opinion. We assumed patients failing first-line voriconazole were switched-to or added-on caspofungin; patients failing first-line LAMB or caspofungin were switched-to or added-on voriconazole. Base-case evaluation included drug management and additional hospitalization costs due to severe adverse events. Treatment success rates were obtained from pivotal clinical trials (voriconazole, 52.8%; LAMB, 50.0%; caspofungin, 33%). First-line treatment duration was assumed 24 days for voriconazole (14-day 4-6mg/kg/d IV followed by 10-day 200mg/BID oral), IV LAMB (3-5mg/kg/d), and IV caspofungin (50-70mg/d); second-line treatment duration was assumed 15 days regardless of therapy. Results from our model showed considerably lower total treatment costs for voriconazole (LBP14,144,427/$9,411) than LAMB (LBP32,982,623/$21,945) and caspofungin (LBP26,202,736/$17,434) in Lebanon. Voriconazole cost savings primarily resulted from lower drug costs, higher treatment efficacy, and shorter IV LOT compared to LAMB and caspofungin. First-line voriconazole therapy remained cost saving even when the entire voriconazole treatment course was administered intravenously. Cost drivers included treatment efficacy and i.v. drug per-day costs (voriconazole LBP462,914/$308; LAMB LBP1,130,232/$752; caspofungin LBP766,513/$510). Results from this study suggest that voriconazole is cost-saving compared to LAMB and caspofungin in the treatment of IA from payer perspectives in Lebanon." @default.
- W4251268891 created "2022-05-12" @default.
- W4251268891 creator A5022459235 @default.
- W4251268891 creator A5026321359 @default.
- W4251268891 creator A5027850504 @default.
- W4251268891 creator A5031938441 @default.
- W4251268891 creator A5056944887 @default.
- W4251268891 date "2016-11-01" @default.
- W4251268891 modified "2023-10-18" @default.
- W4251268891 title "Cost Analysis of Voriconazole Versus Liposomal Amphotericin B And Caspofungin For Primary Therapy of Invasive Aspergillosis Among High-Risk Hematologic Cancer Patients In Lebanon" @default.
- W4251268891 doi "https://doi.org/10.1016/j.jval.2016.09.1366" @default.
- W4251268891 hasPublicationYear "2016" @default.
- W4251268891 type Work @default.
- W4251268891 citedByCount "0" @default.
- W4251268891 crossrefType "journal-article" @default.
- W4251268891 hasAuthorship W4251268891A5022459235 @default.
- W4251268891 hasAuthorship W4251268891A5026321359 @default.
- W4251268891 hasAuthorship W4251268891A5027850504 @default.
- W4251268891 hasAuthorship W4251268891A5031938441 @default.
- W4251268891 hasAuthorship W4251268891A5056944887 @default.
- W4251268891 hasBestOaLocation W42512688911 @default.
- W4251268891 hasConcept C126322002 @default.
- W4251268891 hasConcept C141071460 @default.
- W4251268891 hasConcept C16005928 @default.
- W4251268891 hasConcept C197934379 @default.
- W4251268891 hasConcept C203014093 @default.
- W4251268891 hasConcept C2776391196 @default.
- W4251268891 hasConcept C2779548794 @default.
- W4251268891 hasConcept C2780402444 @default.
- W4251268891 hasConcept C2780690907 @default.
- W4251268891 hasConcept C71924100 @default.
- W4251268891 hasConceptScore W4251268891C126322002 @default.
- W4251268891 hasConceptScore W4251268891C141071460 @default.
- W4251268891 hasConceptScore W4251268891C16005928 @default.
- W4251268891 hasConceptScore W4251268891C197934379 @default.
- W4251268891 hasConceptScore W4251268891C203014093 @default.
- W4251268891 hasConceptScore W4251268891C2776391196 @default.
- W4251268891 hasConceptScore W4251268891C2779548794 @default.
- W4251268891 hasConceptScore W4251268891C2780402444 @default.
- W4251268891 hasConceptScore W4251268891C2780690907 @default.
- W4251268891 hasConceptScore W4251268891C71924100 @default.
- W4251268891 hasIssue "7" @default.
- W4251268891 hasLocation W42512688911 @default.
- W4251268891 hasOpenAccess W4251268891 @default.
- W4251268891 hasPrimaryLocation W42512688911 @default.
- W4251268891 hasRelatedWork W1968772793 @default.
- W4251268891 hasRelatedWork W1989263970 @default.
- W4251268891 hasRelatedWork W1994312167 @default.
- W4251268891 hasRelatedWork W2049181212 @default.
- W4251268891 hasRelatedWork W2096795316 @default.
- W4251268891 hasRelatedWork W2113971091 @default.
- W4251268891 hasRelatedWork W2121903842 @default.
- W4251268891 hasRelatedWork W2127993231 @default.
- W4251268891 hasRelatedWork W2615986654 @default.
- W4251268891 hasRelatedWork W4236380909 @default.
- W4251268891 hasVolume "19" @default.
- W4251268891 isParatext "false" @default.
- W4251268891 isRetracted "false" @default.
- W4251268891 workType "article" @default.